ams and Precision Biomonitoring to develop saliva antigen tester for Covid-19 29 Dec 2020 Based on ams's spectral sensors and PB's virus detection capabilities to enable âswift and conclusive test results.â The partnership will see amsâ innovative spectral sensor technology paired with Precision Biomonitoringâs lateral flow and digital capabilities. The combination is expected to re-imagine mass testing devices for Covid-19. Initial results, on inactivated virus particles, âindicate a very good sensitivity in the order of cycle time (CT) 31, which could lead to the identification of asymptomatic persons,â say the partners. Dr. Mario Thomas, CEO, Precision Biomonitoring, commented, âThe pandemic will continue to be part of our lives well into the new year. This partnership with ams will continue to provide innovative solutions urgently needed by government and authorities to help track and control this virus.